Nureca Limited has informed the stock exchange regarding the resignation of Chief Financial Officer.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited's board meeting on May 29, 2026 approved audited FY26 results showing revenue of ₹1,472.10 million (up 28% YoY) and net profit of ₹2.97 million versus loss of ₹6.68 million in FY25. CFO Mr. Naresh Gupta resigned effective June 26, 2026 citing better career opportunities, and Mr. Chander Kant (internal promotion from Manager Finance) will take over as CFO from June 27, 2026. The board also approved appointment of Ms. Smita Goyal (sister-in-law of existing directors) as Whole Time Director from June 1, 2026, and reappointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (Managing Director) for three-year terms each. Additionally, the board approved ₹100 crore capex for manufacturing medical devices and healthcare products at Derabassi, Punjab, and plans to purchase adjacent land for expansion. A share buyback at ₹330 per share was completed in Q3 FY26.
The CFO transition appears smooth with internal succession, reducing execution risk. However, the appointment of a family member (Ms. Smita Goyal) to the board raises governance concerns. Strong revenue growth and return to profitability are positive, though Q4 showed a ₹66.25 million loss partly due to a ₹83.37 million fair value loss on investments. The capex approval signals expansion in the healthcare products segment.